Injection site reactions with the use of biological agents

Dermatologic TherapyVolume 32, Issue 2 e12817 Therapeutic Hotline: Short Paper Injection site reactions with the use of biological agents Elena Thomaidou, Elena Thomaidou orcid.org/0000-0002-8029-0209 Department of Dermatology, Hadassah Medical Center, Hebrew University of Jerusalem, The Faculty of Medicine, Jerusalem, IsraelSearch for more papers by this authorYuval Ramot, Corresponding Author Yuval Ramot yramot@gmail.com orcid.org/0000-0002-8606-8385 Department of Dermatology, Hadassah Medical Center, Hebrew University of Jerusalem, The Faculty of Medicine, Jerusalem, Israel Correspondence Yuval Ramot, Department of Dermatology, Hadassah Medical Center, Hebrew University of Jerusalem, The Faculty of Medicine, Jerusalem 9112001, Israel. Email: yramot@gmail.comSearch for more papers by this author Elena Thomaidou, Elena Thomaidou orcid.org/0000-0002-8029-0209 Department of Dermatology, Hadassah Medical Center, Hebrew University of Jerusalem, The Faculty of Medicine, Jerusalem, IsraelSearch for more papers by this authorYuval Ramot, Corresponding Author Yuval Ramot yramot@gmail.com orcid.org/0000-0002-8606-8385 Department of Dermatology, Hadassah Medical Center, Hebrew University of Jerusalem, The Faculty of Medicine, Jerusalem, Israel Correspondence Yuval Ramot, Department of Dermatology, Hadassah Medical Center, Hebrew University of Jerusalem, The Faculty of Medicine, Jerusalem 9112001, Israel. Email: yramot@gmail.comSearch for more papers by this author First published: 13 January 2019 https://doi.org/10.1111/dth.12817Citations: 34Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat Abstract Injection site reactions (ISRs) are a local phenomenon defined as a constellation of symptoms, including swelling, erythema, pruritus, and pain around the site of injection. This article reviews the different aspects of ISRs, including their epidemiology and pathogenesis, and provides practical guidance to diagnose and treat such reactions. More focus is given to food and drug administration (FDA)-approved biological agents and biosimilars, which are licensed mainly for the treatment of dermatological conditions, including psoriasis, atopic dermatitis, and chronic urticaria. ISRs are major complications of all FDA-approved self-injectable biological agents, both in adults and children, with studies showing an incidence rate of 0.5–40%. The article emphasizes that ISRs are not correlated with drug efficacy or development of antidrug antibodies. Therefore, misunderstanding of the pathophysiology of the ISRs, most of them not being allergic or immunogenic reactions, might result in unnecessary discontinuation of the treatment. Almost all local reactions to subcutaneously administered biological agents can be prevented by changing the injection techniques, patient education, and training. CONFLICT OF INTEREST Yuval Ramot has received speaker honorarium and consultancy fees from Pfizer, AbbVie, Novartis, Janssen, and Eli Lilli. Citing Literature Supporting Information Filename Description DTH12817-sup-0001-TableS1.pdfPDF document, 964.1 KB Table S1. FDA-approved subcutaneous biological agents and biosimilars for the treatment of psoriasis, psoriatic arthritis, atopic dermatitis, and chronic urticaria. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article. Volume32, Issue2March/April 2019e12817 RelatedInformation